Terns Pharmaceuticals Inc (TERN)
6.17
-0.38
(-5.80%)
USD |
NASDAQ |
Nov 15, 16:00
6.17
0.00 (0.00%)
After-Hours: 20:00
Terns Pharmaceuticals Research and Development Expense (TTM): 69.23M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 69.23M |
| March 31, 2024 | 65.03M |
| December 31, 2023 | 63.50M |
| September 30, 2023 | 56.70M |
| June 30, 2023 | 54.03M |
| March 31, 2023 | 48.54M |
| December 31, 2022 | 39.62M |
| September 30, 2022 | 38.42M |
| Date | Value |
|---|---|
| June 30, 2022 | 33.41M |
| March 31, 2022 | 30.71M |
| December 31, 2021 | 31.31M |
| September 30, 2021 | 29.62M |
| June 30, 2021 | 27.87M |
| March 31, 2021 | 29.52M |
| December 31, 2020 | 28.03M |
| September 30, 2020 | 27.82M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
27.82M
Minimum
Sep 2020
69.23M
Maximum
Jun 2024
42.08M
Average
35.92M
Median
Research and Development Expense (TTM) Benchmarks
| Eli Lilly and Co | 10.53B |
| Viking Therapeutics Inc | 91.16M |
| Biomarin Pharmaceutical Inc | 779.92M |
| Elite Pharmaceuticals Inc | 7.903M |
| Verrica Pharmaceuticals Inc | 15.99M |